Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.4046
-0.0248 (-5.78%)
At close: Feb 9, 2026, 4:00 PM EST
0.4023
-0.0023 (-0.57%)
After-hours: Feb 9, 2026, 7:45 PM EST
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$83,149
Profits / Employee
-$3,672,051
Market Cap
29.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| Passage Bio | 60 |
| Evaxion | 46 |
| Cue Biopharma | 41 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| Lantern Pharma | 24 |
| AN2 Therapeutics | 22 |
OTLK News
- 4 weeks ago - Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewsWire
- 5 weeks ago - US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters
- 5 weeks ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 6 weeks ago - Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again - Seeking Alpha
- 6 weeks ago - Outlook Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 - GlobeNewsWire
- 2 months ago - Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire